Stockscreener 앱 받기
54.48
0.85%
0.46
시간 외 거래:
55.00
0.52
+0.95%
전일 마감가:
$54.02
열려 있는:
$53.85
하루 거래량:
78,415
Relative Volume:
0.37
시가총액:
$364.59M
수익:
-
순이익/손실:
$-13.72M
주가수익비율:
-27.43
EPS:
-1.9861
순현금흐름:
$-12.20M
1주 성능:
+3.36%
1개월 성능:
+0.70%
6개월 성능:
-31.83%
1년 성능:
+33.50%
1일 변동 폭
$53.65
$55.42
1주일 범위
$50.22
$55.42
52주 변동 폭
$28.40
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
54.48 | 361.51M | 0 | -13.72M | -12.20M | -1.9861 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | Morgan Stanley | Overweight |
| 2025-11-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | 개시 | Leerink Partners | Outperform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-09-09 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-08-26 | 재개 | H.C. Wainwright | Buy |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-19 | 재개 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Piper Sandler | Overweight |
| 2024-10-11 | 개시 | Rodman & Renshaw | Buy |
| 2021-01-28 | 개시 | ROTH Capital | Buy |
모두보기
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
(MNPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MNPR (Monopar Therapeutics Inc.) slips 2.56% after Q4 2025 earnings miss on larger than expected per share loss.ROIC - Xã Thanh Hà
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill
Monopar Therapeutics stock maintained at Buy by Lake Street on trial data - Investing.com Canada
Monopar Therapeutics stock maintained at Buy by BTIG on trial data - Investing.com Canada
Monopar Reports Phase 3 Data Showing ALXN1840 Provides Greater Neurologic Benefit Versus Standard of Care in Wilson Disease Patients - Minichart
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification - TipRanks
Monopar Highlights Strong Phase 3 Data for ALXN1840 - TipRanks
Monopar (MNPR) unveils Phase 3 ALXN1840 neurologic gains and plans mid-2026 NDA - Stock Titan
Lake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Monopar Therapeutics (MNPR) Shows Promising Results in Wilson Di - GuruFocus
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 - The Manila Times
Monopar Therapeutics Reports Positive Phase 3 Trial Results for ALXN1840 in Wilson Disease Patients at AAN Annual Meeting 2026 - Quiver Quantitative
Wilson disease study: 9% worsened on ALXN1840 vs 25% on standard care - Stock Titan
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Monopar Therapeutics (MNPR) Stock Sector Perform (Weakens) 2026-04-16High Volume Stocks - Xã Vĩnh Công
How (MNPR) Movements Inform Risk Allocation Models - Stock Traders Daily
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Is Monopar Therapeutics Inc a momentum stock2026 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Is Monopar Therapeutics Inc stock technically oversold2026 Risk Factors & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst - defenseworld.net
Monopar Therapeutics Inc (MNPR) Gets a Buy from JonesTrading - The Globe and Mail
Brookline Capital Markets Forecasts MNPR Q1 Earnings - MarketBeat
Gains Report: Will Monopar Therapeutics Inc benefit from sector rotationQuarterly Trade Review & Long Hold Capital Preservation Plans - baoquankhu1.vn
Trading Systems Reacting to (MNPR) Volatility - Stock Traders Daily
MNPR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Monopar Therapeutics Inc. (1IY0.SG) stock price, news, quote and history - Yahoo Finance Singapore
Monopar Therapeutics Inc. (1IY0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
[Form 4] Monopar Therapeutics Insider Trading Activity - Stock Titan
Monopar Therapeutics (MNPR) COO gains shares through RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics Inc. 2025 Annual Report Amendment: Financial Highlights, Corrections, and Key SEC Filings - Minichart
Monopar Therapeutics | 10-K/A: Annual report (Amendment) - Moomoo
Monopar (NASDAQ: MNPR) 10-K/A shows $13.7M loss but strong cash - Stock Titan
HC Wainwright Brokers Reduce Earnings Estimates for MNPR - MarketBeat
Monopar Therapeutics Inc. (1IY0.SG) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
MNPR SEC FilingsMonopar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MNPR's Rating Maintains 'Buy' by Chardan Capital: March 30, 2026 - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Monopar Therapeutics stock price target maintained at $104 by BTIG - Investing.com Canada
Monopar Therapeutics Inc. Q4 and Full Year 2025 Earnings: Net Loss Narrows to $13.7M - Bayelsa Watch
Monopar Therapeutics (STU:1IY0) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - gurufocus.com
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - The Manila Times
Leerink reiterates Monopar stock rating on Wilson disease drug potential By Investing.com - Investing.com Canada
Raymond James reiterates Monopar stock rating on NDA timing shift By Investing.com - Investing.com Canada
Is Flanigans Enterprises Inc stock a hidden gem2026 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MNPR: ALXN1840 advances toward NDA in 2026 as financials improve and cash reserves strengthen - TradingView
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):